Immune Design Corp (NASDAQ:IMDZ) has been given a consensus recommendation of “Buy” by the seven analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $10.63.
IMDZ has been the subject of a number of recent research reports. Cowen restated a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. Zacks Investment Research upgraded shares of Immune Design from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Tuesday, January 2nd. Finally, Jefferies Group reiterated a “buy” rating and issued a $8.00 target price on shares of Immune Design in a research note on Thursday, March 15th.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Anson Funds Management LP bought a new stake in shares of Immune Design in the 4th quarter worth $313,000. TIAA CREF Investment Management LLC grew its stake in shares of Immune Design by 49.0% in the 4th quarter. TIAA CREF Investment Management LLC now owns 63,192 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 20,777 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Immune Design by 71.4% in the 4th quarter. Teachers Advisors LLC now owns 56,367 shares of the biotechnology company’s stock worth $220,000 after acquiring an additional 23,475 shares in the last quarter. Bain Capital Public Equity Management LLC grew its stake in shares of Immune Design by 155.3% in the 4th quarter. Bain Capital Public Equity Management LLC now owns 3,316,769 shares of the biotechnology company’s stock worth $12,935,000 after acquiring an additional 2,017,756 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of Immune Design by 82.3% in the 4th quarter. California State Teachers Retirement System now owns 50,518 shares of the biotechnology company’s stock worth $197,000 after acquiring an additional 22,799 shares in the last quarter. Hedge funds and other institutional investors own 53.78% of the company’s stock.
IMDZ stock traded up $0.05 during midday trading on Monday, reaching $3.20. 267,295 shares of the company’s stock traded hands, compared to its average volume of 493,006. The firm has a market capitalization of $151.59, a PE ratio of -1.83 and a beta of 1.89. Immune Design has a 52 week low of $2.80 and a 52 week high of $13.05.
Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings results on Wednesday, March 14th. The biotechnology company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.10. The business had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.81 million. Immune Design had a negative net margin of 720.81% and a negative return on equity of 57.56%. research analysts anticipate that Immune Design will post -1.33 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Immune Design Corp (IMDZ) Receives Average Rating of “Buy” from Brokerages” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/09/immune-design-corp-imdz-receives-average-rating-of-buy-from-brokerages.html.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.